ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Short Interest Update

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) was the target of a large decrease in short interest during the month of July. As of July 31st, there was short interest totalling 5,200 shares, a decrease of 35.0% from the July 15th total of 8,000 shares. Based on an average trading volume of 17,200 shares, the days-to-cover ratio is currently 0.3 days.

ProShares Ultra Nasdaq Biotechnology Stock Up 3.1 %

BIB stock traded up $1.93 during midday trading on Thursday, reaching $64.27. 6,633 shares of the company were exchanged, compared to its average volume of 28,430. The stock’s 50-day simple moving average is $61.90 and its 200 day simple moving average is $57.94. ProShares Ultra Nasdaq Biotechnology has a 1-year low of $40.10 and a 1-year high of $69.56.

ProShares Ultra Nasdaq Biotechnology Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, July 3rd. Investors of record on Wednesday, June 26th were given a $0.2648 dividend. This is an increase from ProShares Ultra Nasdaq Biotechnology’s previous quarterly dividend of $0.04. The ex-dividend date was Wednesday, June 26th. This represents a $1.06 annualized dividend and a yield of 1.65%.

Institutional Trading of ProShares Ultra Nasdaq Biotechnology

Several institutional investors and hedge funds have recently bought and sold shares of BIB. Texas Capital Bank Wealth Management Services Inc acquired a new position in ProShares Ultra Nasdaq Biotechnology in the 1st quarter valued at $288,000. Westwood Wealth Management purchased a new position in shares of ProShares Ultra Nasdaq Biotechnology during the 1st quarter worth about $575,000. Toth Financial Advisory Corp increased its position in ProShares Ultra Nasdaq Biotechnology by 132.3% during the 1st quarter. Toth Financial Advisory Corp now owns 26,111 shares of the exchange traded fund’s stock worth $1,502,000 after purchasing an additional 14,870 shares in the last quarter. Clarity Capital Partners LLC acquired a new stake in ProShares Ultra Nasdaq Biotechnology in the fourth quarter valued at approximately $201,000. Finally, IMC Chicago LLC acquired a new stake in ProShares Ultra Nasdaq Biotechnology in the fourth quarter valued at approximately $2,435,000.

About ProShares Ultra Nasdaq Biotechnology

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.